1. Home
  2. WAL vs DMAC Comparison

WAL vs DMAC Comparison

Compare WAL & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WAL
  • DMAC
  • Stock Information
  • Founded
  • WAL 1994
  • DMAC 2000
  • Country
  • WAL United States
  • DMAC United States
  • Employees
  • WAL N/A
  • DMAC N/A
  • Industry
  • WAL Major Banks
  • DMAC Biotechnology: Pharmaceutical Preparations
  • Sector
  • WAL Finance
  • DMAC Health Care
  • Exchange
  • WAL Nasdaq
  • DMAC Nasdaq
  • Market Cap
  • WAL 9.3B
  • DMAC 178.0M
  • IPO Year
  • WAL 2005
  • DMAC N/A
  • Fundamental
  • Price
  • WAL $84.42
  • DMAC $3.63
  • Analyst Decision
  • WAL Strong Buy
  • DMAC Strong Buy
  • Analyst Count
  • WAL 16
  • DMAC 2
  • Target Price
  • WAL $96.19
  • DMAC $8.00
  • AVG Volume (30 Days)
  • WAL 813.9K
  • DMAC 325.9K
  • Earning Date
  • WAL 07-17-2025
  • DMAC 08-06-2025
  • Dividend Yield
  • WAL 1.79%
  • DMAC N/A
  • EPS Growth
  • WAL 6.13
  • DMAC N/A
  • EPS
  • WAL 7.28
  • DMAC N/A
  • Revenue
  • WAL $3,049,400,000.00
  • DMAC N/A
  • Revenue This Year
  • WAL $13.26
  • DMAC N/A
  • Revenue Next Year
  • WAL $9.54
  • DMAC N/A
  • P/E Ratio
  • WAL $11.69
  • DMAC N/A
  • Revenue Growth
  • WAL 11.37
  • DMAC N/A
  • 52 Week Low
  • WAL $57.05
  • DMAC $2.98
  • 52 Week High
  • WAL $98.10
  • DMAC $6.82
  • Technical
  • Relative Strength Index (RSI)
  • WAL 68.66
  • DMAC 44.55
  • Support Level
  • WAL $82.56
  • DMAC $3.48
  • Resistance Level
  • WAL $86.28
  • DMAC $3.88
  • Average True Range (ATR)
  • WAL 2.25
  • DMAC 0.26
  • MACD
  • WAL 0.70
  • DMAC 0.00
  • Stochastic Oscillator
  • WAL 87.01
  • DMAC 30.10

About WAL Western Alliance Bancorporation (DE)

Western Alliance Bancorporation is a Las Vegas-based holding company with regional banks operating in Nevada, Arizona, and California. The bank offers retail banking services and focuses on mortgages for retail customers and commercial loans. The company's reportable segments are Commercial segment includes provides commercial banking and treasury management products and services to small and middle-market businesses, specialized banking services to sophisticated commercial institutions and investors within niche industries, as well as financial services to the real estate industry. Consumer Related segment offers both commercial banking services to enterprises in consumer-related sectors and consumer banking services, such as residential mortgage banking and Corporate & Other.

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

Share on Social Networks: